{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T19:11:52Z","timestamp":1771614712463,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","thrombosisresearch.com","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.thromres.2024.02.007","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T08:44:05Z","timestamp":1707813845000},"page":"4-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Smaller nadroparin dose reductions required for patients with renal impairment: A multicenter cohort study"],"prefix":"10.1016","volume":"236","author":[{"given":"Renate C.A.E.","family":"van Uden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tessa C.C.","family":"Jaspers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karina","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karlijn J.","family":"van Stralen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Maat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nakisa","family":"Khorsand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hein A.W.","family":"van Onzenoort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora L.","family":"Swart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harmen J.","family":"Huls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron A.A.","family":"Math\u00f4t","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha\u00ebl V.","family":"Lukens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia M.L.A.","family":"van den Bemt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthijs L.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2024.02.007_bb0005","series-title":"Scottish Intercollegiate Guidelines Network (SIGN). Prevention and Management of Venous Thromboembolism","year":"2010"},{"issue":"1","key":"10.1016\/j.thromres.2024.02.007_bb0010","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/jth.12070","article-title":"International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"11","author":"Farge","year":"2013","journal-title":"J. Thromb. Haemost."},{"issue":"2 Suppl","key":"10.1016\/j.thromres.2024.02.007_bb0015","doi-asserted-by":"crossref","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2024.02.007_bb0020","first-page":"54(3)","volume":"2019","author":"Konstantinides","year":"2019","journal-title":"Eur. Respir. J."},{"issue":"22","key":"10.1016\/j.thromres.2024.02.007_bb0025","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1182\/bloodadvances.2018024893","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy","volume":"2","author":"Witt","year":"2018","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.thromres.2024.02.007_bb0030","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2141.2005.05953.x","article-title":"Guidelines on the use and monitoring of heparin","volume":"133","author":"Baglin","year":"2006","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.thromres.2024.02.007_bb0035","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/archinte.160.2.229","article-title":"Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian thrombosis study group","volume":"160","author":"Hull","year":"2000","journal-title":"Arch. Intern. Med."},{"issue":"1","key":"10.1016\/j.thromres.2024.02.007_bb0040","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0002-8703(03)00121-2","article-title":"Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies","volume":"146","author":"Spinler","year":"2003","journal-title":"Am. Heart J."},{"issue":"5","key":"10.1016\/j.thromres.2024.02.007_bb0045","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1378\/chest.125.5.1616","article-title":"Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome","volume":"125","author":"Macie","year":"2004","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.thromres.2024.02.007_bb0050","doi-asserted-by":"crossref","first-page":"673","DOI":"10.7326\/0003-4819-144-9-200605020-00011","article-title":"Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency","volume":"144","author":"Lim","year":"2006","journal-title":"Ann. Intern. Med."},{"issue":"8","key":"10.1016\/j.thromres.2024.02.007_bb0055","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00228-015-1880-5","article-title":"A systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiency","volume":"71","author":"Atiq","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.thromres.2024.02.007_bb0060","series-title":"Richtlijn Antistolling met laagmoleculairgewicht heparines (LMWH) bij nierinsuffici\u00ebntie [in Dutch]","author":"Nederlandse federatie van Nefrologie (NfN)","year":"2012"},{"issue":"5","key":"10.1016\/j.thromres.2024.02.007_bb0065","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jacc.2009.03.062","article-title":"Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb\/IIIa inhibitors or thienopyridines: results from the OASIS 5 (fifth organization to assess strategies in ischemic syndromes) trial","volume":"54","author":"Jolly","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.thromres.2024.02.007_bb0070","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/annonc\/mdj059","article-title":"Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial","volume":"17","author":"Karthaus","year":"2006","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.thromres.2024.02.007_bb0075","series-title":"Richtlijn antitrombotisch beleid. Behandeling LMWH bij nierfunctiestoornissen en risico op VTE [in Dutch]","author":"Dutch Internists Association (NIV)","year":"2021"},{"key":"10.1016\/j.thromres.2024.02.007_bb0080","author":"Royal Dutch Pharmacists Assciation (KNMP)"},{"key":"10.1016\/j.thromres.2024.02.007_bb0085","author":"IBM Micromedex"},{"key":"10.1016\/j.thromres.2024.02.007_bb0090","series-title":"The Renal Drug Handbook","author":"Ashley","year":"2014"},{"key":"10.1016\/j.thromres.2024.02.007_bb0095","unstructured":"Nadroparin Calcium Aspen 3,800 I.U. anti-Xa\/0.4 ml solution for injectio in a prefilles syringe (SmPC) [Internet]. 2016 [cited 2022-10-28]."},{"issue":"10","key":"10.1016\/j.thromres.2024.02.007_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0239222","article-title":"Dosage reduction of low weight heparin in patients with renal dysfunction: effects on anti-Xa levels and clinical outcomes","volume":"15","author":"Hornung","year":"2020","journal-title":"PLoS One"},{"issue":"2\u20133","key":"10.1016\/j.thromres.2024.02.007_bb0105","first-page":"170","article-title":"Conjectures and refutations on the mode of action of heparins. The limited importance of anti-factor xa activity as a pharmaceutical mechanism and a yardstick for therapy","volume":"29","author":"B\u00e9guin","year":"1999","journal-title":"Haemostasis"},{"issue":"9","key":"10.1016\/j.thromres.2024.02.007_bb0110","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."},{"issue":"3","key":"10.1016\/j.thromres.2024.02.007_bb0115","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1532\/LH96.05028","article-title":"How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? A laboratory perspective","volume":"11","author":"Favaloro","year":"2005","journal-title":"Lab. Hematol."},{"issue":"2","key":"10.1016\/j.thromres.2024.02.007_bb0120","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000477474","article-title":"Empirically reduced dosages of Tinzaparin in patients with moderate-to-severe renal insufficiency Lead to inadequate anti-Xa levels","volume":"137","author":"Olie","year":"2017","journal-title":"Nephron"},{"issue":"6","key":"10.1016\/j.thromres.2024.02.007_bb0125","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1592\/phco.2005.25.6.817","article-title":"Peak antifactor xa activity produced by dalteparin treatment in patients with renal impairment compared with controls","volume":"25","author":"Shprecher","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.thromres.2024.02.007_bb0130","series-title":"Prevalentie van correcte anti-Xa-bloedspiegels bij pati\u00ebnten met verminderde nierfunctie op basis van dosisadvies conform richtlijn Nederlandse Federatie voor Nefrologie [Internet]","author":"Smit","year":"2016"},{"issue":"10","key":"10.1016\/j.thromres.2024.02.007_bb0135","first-page":"360","article-title":"Dalteparin and anti-Xa: a complex interplay of therapeutic drug monitoring","volume":"77","author":"van Bergen","year":"2019","journal-title":"Neth. J. Med."},{"key":"10.1016\/j.thromres.2024.02.007_bb0140","article-title":"Anti-Xa-activiteit van therapeutisch nadroparine bij verminderde nierfunctie en behandeling conform richtlijn Nederlandse federatie voor Nefrologie: vergelijking met standaarddosis bij normale nierfunctie","volume":"1","author":"van Ojik","year":"2016","journal-title":"Nederlands Platform voor Farmaceutisch Onderzoek."},{"key":"10.1016\/j.thromres.2024.02.007_bb0145","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/2162-3619-2-21","article-title":"Tinzaparin and other low-molecular-weight heparins: what is the evidence for differential dependence on renal clearance?","volume":"2","author":"Johansen","year":"2013","journal-title":"Exp. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.thromres.2024.02.007_bb0150","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1093\/ndt\/gfi004","article-title":"The heparins: all a nephrologist should know","volume":"20","author":"Hetzel","year":"2005","journal-title":"Nephrol. Dial. Transplant."},{"issue":"1","key":"10.1016\/j.thromres.2024.02.007_bb0155","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1046\/j.1365-2257.1999.00183.x","article-title":"Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin","volume":"21","author":"Kovacs","year":"1999","journal-title":"Clin. Lab. Haematol."},{"issue":"4\u20135","key":"10.1016\/j.thromres.2024.02.007_bb0160","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/0049-3848(92)90213-T","article-title":"Correlation between anti-Xa and occurrence of thrombosis and haemorrhage in post-surgical patients treated with either Logiparin (LMWH) or unfractionated heparin. Post-surgery Logiparin Study Group","volume":"65","author":"Bara","year":"1992","journal-title":"Thromb. Res."},{"issue":"5","key":"10.1016\/j.thromres.2024.02.007_bb0165","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1097\/01.CCM.0000059725.60509.A0","article-title":"Prophylactic anticoagulation with enoxaparin: is the subcutaneous route appropriate in the critically ill?","volume":"31","author":"Priglinger","year":"2003","journal-title":"Crit. Care Med."},{"issue":"9309","key":"10.1016\/j.thromres.2024.02.007_bb0170","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(02)07920-5","article-title":"Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors","volume":"359","author":"D\u00f6rffler-Melly","year":"2002","journal-title":"Lancet"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824000422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824000422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T14:18:04Z","timestamp":1717251484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384824000422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":34,"alternative-id":["S0049384824000422"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2024.02.007","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Smaller nadroparin dose reductions required for patients with renal impairment: A multicenter cohort study","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2024.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}